Sign Up
OverviewAPI
Novo Nordisk and Eli Lilly are set to maintain market dominance in the GLP-1 hormone-mimicking drugs sector for diabetes and obesity, outpacing their competitors like Ozempic and Mounjaro. Factors such as first-mover advantage, robust drug pipelines, manufacturing capacity, and data superiority contribute to their stronghold. The market is projected to reach $100 billion by 2030 with Novo and Lilly leading the way.

Ask a question